サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：RNA療法臨床試験市場規模、シェア、動向分析レポート：モダリティ別、フェーズ別、治療領域別、地域別、セグメント予測、2023年～2030年
市場調査レポート
商品コード
1321424

RNA療法臨床試験市場規模、シェア、動向分析レポート：モダリティ別、フェーズ別、治療領域別、地域別、セグメント予測、2023年～2030年

RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Modality, By Phase, By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
RNA療法臨床試験市場規模、シェア、動向分析レポート：モダリティ別、フェーズ別、治療領域別、地域別、セグメント予測、2023年～2030年
出版日: 2023年07月24日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

RNA療法臨床試験市場の成長と動向

Grand View Research社の最新レポートによると、世界のRNA療法臨床試験市場規模は2030年までに35億米ドルに達する見込みです。

同市場は2023年から2030年にかけてCAGR 3.84％で成長すると予測されています。新興国市場の成長は、バイオテクノロジー企業や製薬企業のエスカレートによるもので、感染症や希少疾患の負担増、RNAベースのCOVID-19ワクチンの成功率の上昇、規制当局の承認、個別化医薬品の需要が市場成長の原動力となっています。

その上、RNA療法は病気の治療や予防のための有望な治療アプローチとして機能し、いくつかのRNA臨床試験の増加をもたらしています。さらに、さまざまな種類のRNAに関する長期的な調査活動や、さまざまなヒトの病気や障害を治療するRNAの能力が、市場の強い需要につながっています。また、RNAそのものが薬物や標的として機能するRNA治療の潜在的な利点は、希少疾患や治療困難な疾患に対する新薬開発の革新的なアプローチとして機能しています。

世界的に、感染症や希少疾患は依然として死因の上位を占めており、バイオテクノロジー企業や製薬企業の新薬開発への注目は高まっています。このため、RNAを用いた治療法の技術革新が進み、RNA治療の臨床試験に対する膨大な需要が生まれています。さらに、希少疾患は依然としてRNA療法が最もターゲットとする治療領域です。

さらに、米国食品医薬品局（FDA）によると、2022年12月現在、米国では7,000を超える希少疾患が3,000万人以上に影響を及ぼしており、欧州委員会によると、2023年2月現在、欧州では最大3,600万人が希少疾患を抱えています。EUには6000以上の明確な希少疾患があります。同様に、RNAの機能と疾病予防における役割の理解が進むにつれて、様々なRNAの応用が促進されています。

COVID-19パンデミックはRNA療法臨床試験市場の成長に大きな影響を与えました。製薬会社やバイオテクノロジー企業がワクチン開発、研究開発活動に突然注力したことで、世界中のRNA臨床試験は確実に混乱しました。しかし、RNAベースのCOVID-19ワクチン開発に対する研究者の関心の高まりが、市場のプラス成長を支えています。さらに、他の感染症や腫瘍の適応症に対するRNAの使用にも関心が集まっています。こうした要因が市場の成長を後押ししています。

さらに、主要参入企業は、世界な事業展開と製品ポートフォリオを拡大するために、提携、契約、共同研究、上市などの戦略に取り組んでいます。例えば、2021年3月、IQVIA Company社は、第3相COVID-19ワクチン臨床試験のためのJanssen Research &Development, LLC社との提携を発表しました。この試験では、バーチャル監督、遠隔医療技術、デジタル患者エンゲージメント戦略を組み合わせることで、遠隔試験とオンサイト試験の両方をサポートします。

RNA療法臨床試験市場レポートハイライト

  • メッセンジャーRNAセグメントは、遺伝子発現に関する研究者の増加、技術の進歩がセグメント成長に寄与しているため、2022年に35.7%の最大売上シェアを占めました。
  • フェーズIIセグメントは、2022年に41.3%の収益シェアでRNA療法臨床試験市場を独占しました。RNA療法の有効性とRNA臨床試験の安全性がセグメント成長の原動力となると思われます。
  • 2022年には、希少疾患分野が市場を独占し、21.8%の売上シェアを占めました。成長の主な要因としては、さまざまな種類の希少疾患の負担が増加していることが挙げられます。また、市場参入企業による研究開発費も市場成長の原動力となっています。
  • 北米は2022年に36.6%の最大の売上シェアを占めました。定評のある市場プレイヤーの存在、希少疾患の負担増、RNAに関する調査活動の活発化、臨床試験の増加などがこの地域の成長を後押ししています。
  • さらに、絶え間ない技術革新と臨床研究・臨床試験の増加がこの地域の市場成長を後押ししています。例えば、2022年12月、ModernaとMerckは、KEYTRUDA併用個別化mRNAがんワクチンであるmRNA-4157/V940の第2b相KEYNOTE-942/mRNA-4157-P201試験に言及しました。これはメラノーマのステージIII/IV患者治療用のmRNAがんワクチンです。
  • 市場を独占する主要企業には、IQVIA、Laboratory Corporation of America Holdings、ICON Plc、Charles River Laboratories International, Inc.、PPD Inc.、Syneos Health、Medpace Holdings, Inc.、Novotech、PAREXEL International Corp.、Veristat, LLC.などがあります。

目次

第1章 調査手法と範囲

  • 情報調達
  • 情報またはデータ分析
  • 市場範囲とセグメントの定義
  • 市場モデル

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随的な市場見通し
  • 市場動向と展望
  • 市場力学
  • 市場促進要因の分析
  • 市場抑制要因分析
  • 事業環境分析
    • SWOT分析
    • ポーターのファイブフォース分析
  • COVID-19の影響分析

第4章 モダリティビジネス分析

  • RNA療法臨床試験市場：モダリティ変動分析
  • RNA干渉
  • アンチセンス療法
  • メッセンジャーRNA
  • オリゴヌクレオチド、非アンチセンス、非RNAi

第5章 臨床試験フェーズのビジネス分析

  • RNA療法臨床試験市場：臨床試験フェーズ変動分析
  • フェーズI
  • フェーズ II
  • フェーズⅢ
  • フェーズ IV

第6章 治療領域のビジネス分析

  • RNA療法臨床試験市場：治療領域の変動分析
  • 希少疾患
  • 抗感染症
  • 抗がん剤
  • 神経系
  • 消化器系/代謝系
  • 筋骨格系
  • 心血管、呼吸器
  • 感覚
  • その他

第7章 地域ビジネス分析

  • RNA療法臨床試験の地域別市場シェア、2022年および2030年
  • 北米
    • 北米のRNA療法臨床試験市場、2018年～2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州のRNA療法臨床試験市場、2018年～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • アジア太平洋地域のRNA療法臨床試験市場、2018年～2030年
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ラテンアメリカのRNA療法臨床試験市場、2018年～2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカのRNA療法臨床試験市場、2018年～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 企業の分類
  • 戦略マッピング
    • 合併・買収
    • コラボレーション
    • 新製品の発売
  • 参入企業の概要
    • IQVIA
    • ICON Plc
    • Laboratory Corporation of America Holdings
    • Charles River Laboratories International, Inc.
    • PAREXEL International Corp.
    • Syneos Health
    • Medpace Holdings, Inc.
    • PPD Inc.
    • Novotech
    • Veristat, LLC.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Leading Market Players Anticipated to Witness Highest Growth
  • Table 4 Global RNA Therapy Clinical Trials Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 6 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 7 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 8 North America RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 10 North America RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 11 North America RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 12 U.S. RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 13 U.S. RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 14 U.S. RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 15 Canada RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 16 Canada RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 17 Canada RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 18 Europe RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 20 Europe RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 21 Europe RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 22 UK RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 23 UK RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 24 UK RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 25 Germany RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 26 Germany RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 27 Germany RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 28 France RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 29 France RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 30 France RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 31 Italy RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 32 Italy RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 33 Italy RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 34 Spain RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 35 Spain RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 36 Spain RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 37 Sweden RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 38 Sweden RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 39 Sweden RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 40 Norway RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 41 Norway RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 42 Norway RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 43 Denmark RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 44 Denmark RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 45 Denmark RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 50 Japan RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 51 Japan RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 52 Japan RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 53 China RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 54 China RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 55 China RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 56 India RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 57 India RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 58 India RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 59 Australia RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 60 Australia RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 61 Australia RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 62 South Korea RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 63 South Korea RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 64 South Korea RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 65 Thailand RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 66 Thailand RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 67 Thailand RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 68 Latin America RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 70 Latin America RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 71 Latin America RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 72 Brazil RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 73 Brazil RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 74 Brazil RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 75 Mexico RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 76 Mexico RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 77 Mexico RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 78 Argentina RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 79 Argentina RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 80 Argentina RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 81 Middle East and Africa RNA Therapy Clinical Trials Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East and Africa RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 83 Middle East and Africa RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 84 Middle East and Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 85 South Africa RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 86 South Africa RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 87 South Africa RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 91 UAE RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 92 UAE RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 93 UAE RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)
  • Table 94 Kuwait RNA Therapy Clinical Trials Market, By Modality, 2018 - 2030 (USD Million)
  • Table 95 Kuwait RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2018 - 2030 (USD Million)
  • Table 96 Kuwait RNA Therapy Clinical Trials Market, By Therapeutic Areas 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 RNA Therapy Clinical Trials Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook (2022)
  • Fig. 10 Strategy framework
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 RNA Therapy Clinical Trials Market: Modality movement analysis
  • Fig. 17 RNA Therapy Clinical Trials Market: Modality segment dashboard
  • Fig. 18 RNA Therapy Clinical Trials Market Modality outlook: Key takeaways
  • Fig. 19 RNA interference market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Antisense therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Messenger RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Oligonucleotide, non-antisense, non-RNAi market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 RNA Therapy Clinical Trials Market: Clinical Trials Phase movement analysis
  • Fig. 24 RNA Therapy Clinical Trials Market: Clinical Trials Phase segment dashboard
  • Fig. 25 RNA Therapy Clinical Trials Market: Clinical Trials Phase outlook: Key takeaways
  • Fig. 26 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 RNA Therapy Clinical Trials Market: Therapeutic Areas movement analysis
  • Fig. 31 RNA Therapy Clinical Trials Market: Therapeutic Areas segment dashboard
  • Fig. 32 RNA Therapy Clinical Trials Market: Therapeutic Areas outlook: Key takeaways
  • Fig. 33 Rare Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Anti-infective market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Anticancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Neurological market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Alimentary/Metabolic market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Musculoskeletal market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Cardiovascular Respiratory market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Sensory market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Global RNA Therapy Clinical Trials market, 2018 - 2030 (USD Million)
  • Fig. 43 North America RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 45 Canada RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 46 Europe RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 47 UK RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 48 Germany RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 49 France RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 57 China RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 58 India RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 60 South Korea RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 62 Latin America RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 63 Brazil RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 64 Mexico RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 65 Argentina RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 66 MEA RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 67 South Africa RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 68 Saudi Arabia RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 69 UAE RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 70 Kuwait RNA Therapy Clinical Trials Market, 2018 - 2030 (USD Million)
  • Fig. 71 Heat map analysis
  • Fig. 72 Market differentiator
目次
Product Code: GVR-4-68040-100-2

RNA Therapy Clinical Trials Market Growth & Trends

The global RNA therapy clinical trials market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 3.84% from 2023 to 2030. The growth of the market in emerging countries is due to escalating biotechnology and pharmaceutical companies, the increasing burden of infectious and rare diseases, the growing success rate of RNA-based COVID-19 vaccines, regulatory approval, and demand for personalized medicines drive the market growth.

Besides, RNA therapy acts as a promising therapeutic approach for the treatment or prevention of diseases leading to a rise in several RNA clinical trials. Additionally, long-term research activities on various types of RNAs, and the ability of RNA to treat various human diseases and disorders have led to strong demand for the market. Also, the potential benefit of RNA therapy wherein RNA itself serves as either a drug or a target provides acts as an innovative approach for developing new drugs for rare or difficult-to-treat diseases.

Globally, infectious diseases and rare diseases remain the leading cause of death, which has gained the increased attention of biotechnology and pharmaceutical companies to develop new drugs. This led to the rise in the innovation of RNA-based therapy creating immense requirements for RNA therapy clinical trials. Additionally, rare diseases remain the top targeted therapeutic area by RNA therapies.

Furthermore, according to the US Food & Drug Administration, in December 2022, over 7,000 rare diseases affected more than 30 million people in the U.S. whereas according to European Commission as of February 2023, up to 36 million European population live with a rare disease. There are 6000+ distinct rare diseases in the EU. Likewise, the increasing understanding of RNA functions and their roles in disease prevention has promoted various RNAs application.

The COVID-19 pandemic has greatly impacted the growth of the RNA therapy clinical trials market. The sudden focus of pharmaceutical and biotechnology companies on the development of the vaccine, research, and development activities had certainly disrupted the RNA clinical trials across the globe. However, the increasing interest of researchers to develop an RNA-based COVID-19 vaccine has supported the market with positive growth. Additionally, it has also sparked an interest in RNA use against other infectious diseases and oncology indications. These factors drive the growth of the market.

Furthermore, the key participants engage in strategies such as partnerships, agreements, collaborations, and launches, to expand their global footprints and product portfolio. For instance, in March 2021, IQVIA Company announced the collaboration with Janssen Research & Development, LLC for Phase 3 COVID-19 vaccine clinical trials. The studies will support both remote and on-site studies through a mix of virtual oversight, telehealth technologies, and digital patient engagement strategies.

RNA Therapy Clinical Trail Market Report Highlights

  • The messenger RNA segment held the largest revenue share of 35.7% in 2022 owing to increased researchers' study in gene expression, technology advancement has contributed to the segment growth
  • The Phase II segment dominated the RNA therapy clinical trials market with a revenue share of 41.3% in 2022. The effectiveness of RNA therapy and the safety of RNA clinical trials will drive segment growth
  • In 2022, the rare diseases segment dominated the market and accounted for a revenue share of 21.8%. The key factors contributing to the growth include the growing burden of various types of rare diseases. Also, R&D expenditures made by market players drive the market growth
  • North America held the largest revenue share of 36.6% in 2022. The presence of well-established market players, the increasing burden of rare diseases, growing research activities on RNA, rising number of clinical trials drive the regional growth
  • Additionally, constant innovation and an emerging number of clinical studies and trials drive the market growth in the region. For instance, in December 2022, Moderna & Merck mentioned the phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940 a personalized mRNA cancer vaccine with KEYTRUDA combination. It is an mRNA cancer vaccine for melanoma stage III/IV patient treatment
  • Key players dominating the market include IQVIA; Laboratory Corporation of America Holdings; ICON Plc; Charles River Laboratories International, Inc.; PPD Inc.; Syneos Health; Medpace Holdings, Inc.; Novotech; PAREXEL International Corp.; and Veristat, LLC

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
  • 3.5. Market Driver Analysis
  • 3.6. Market Restraint Analysis
  • 3.7. Business Environment Analysis
    • 3.7.1. SWOT Analysis
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. COVID-19 Impact Analysis

Chapter 4. Modality Business Analysis

  • 4.1. RNA therapy clinical trials Market: Modality Movement Analysis
  • 4.2. RNA interference
    • 4.2.1. RNA interference Market, 2018 - 2030 (USD Million)
  • 4.3. Antisense therapy
    • 4.3.1. Antisense therapy Market, 2018 - 2030 (USD Million)
  • 4.4. Messenger RNA
    • 4.4.1. Messenger RNA Market, 2018 - 2030 (USD Million)
  • 4.5. Oligonucleotide, non-antisense, non-RNAi
    • 4.5.1. Oligonucleotide, non-antisense, non-RNAi Market, 2018 - 2030 (USD Million)

Chapter 5. Clinical Trials Phase Business Analysis

  • 5.1. RNA therapy clinical trials Market: Clinical Trials Phase Movement Analysis
  • 5.2. Phase I
    • 5.2.1. Phase I Market, 2018 - 2030 (USD Million)
  • 5.3. Phase II
    • 5.3.1. Phase II Market, 2018 - 2030 (USD Million)
  • 5.4. Phase III
    • 5.4.1. Phase III Market, 2018 - 2030 (USD Million)
  • 5.5. Phase IV
    • 5.5.1. Phase IV Market, 2018 - 2030 (USD Million)

Chapter 6. Therapeutic Areas Business Analysis

  • 6.1. RNA therapy clinical trials Market: Therapeutic Areas Movement Analysis
  • 6.2. Rare Diseases
    • 6.2.1. Rare Diseases Market, 2018 - 2030 (USD Million)
  • 6.3. Anti-infective
    • 6.3.1. Anti-infective Market, 2018 - 2030 (USD Million)
  • 6.4. Anticancer
    • 6.4.1. Anticancer Market, 2018 - 2030 (USD Million)
  • 6.5. Neurological
    • 6.5.1. Neurological Market, 2018 - 2030 (USD Million)
  • 6.6. Alimentary/Metabolic
    • 6.6.1. Alimentary/Metabolic Market, 2018 - 2030 (USD Million)
  • 6.7. Musculoskeletal
    • 6.7.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
  • 6.8. Cardiovascular Respiratory
    • 6.8.1. Cardiovascular Respiratory Market, 2018 - 2030 (USD Million)
  • 6.9. Sensory
    • 6.9.1. Sensor Market, 2018 - 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. RNA therapy clinical trials Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Regulatory Framework
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. U.S. RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Regulatory Framework
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Canada RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. UK RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Germany RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. France RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Italy RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Spain RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.7. Sweden
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Sweden RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Norway RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.3.9. Denmark
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Denmark RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Japan RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. China RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. India RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Australia RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. South Korea RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Thailand RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Brazil RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Mexico RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Argentina RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. South Africa RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Saudi Arabia RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. UAE RNA therapy clinical trials Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Kuwait RNA therapy clinical trials Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. Merger& Acquisition
    • 8.2.2. Collaborations
    • 8.2.3. New Product Launch
  • 8.3. Participant's overview
    • 8.3.1. IQVIA
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. ICON Plc
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Laboratory Corporation of America Holdings
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Charles River Laboratories International, Inc.
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. PAREXEL International Corp.
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Syneos Health
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Medpace Holdings, Inc.
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. PPD Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Novotech
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Veristat, LLC.
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives